Ardelyx

Ardelyx

Yahoo Finance • 8 days ago

Valeris Welcomes Patient Services Veteran Lauren Cole to Lead Commercial Strategy

JEFFERSONVILLE, Ind. and MORRISVILLE, N.C., Aug. 18, 2026 /PRNewswire/ -- Valeris, an integrated commercialization partner helping life sciences companies connect market access, patient services, and commercial strategy, today announced th... Full story

Yahoo Finance • 19 days ago

Ardelyx falls on lower projected Ibsrela sales, Q2 misses

[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) is down ~13% in Friday morning trading after lowering [https://seekingalpha.com/news/4628428-ardelyx-gaap-eps-of-... Full story

Yahoo Finance • 2 months ago

Ardelyx stock decline attributed to setback in Xphozah appeal

[Judge gavel on the table with blurry books in the background] greenleaf123 Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) shares fell ~6% on Friday after the company lost an appeal against the Health and Human Services Department... Full story

Yahoo Finance • 2 months ago

What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?

Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is cur... Full story

Yahoo Finance • 3 months ago

Should You Buy Ardelyx (ARDX)?

We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Ardelyx Inc. (NASDAQ:ARDX) ranks #9 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 30 Biotech co... Full story

Yahoo Finance • 4 months ago

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical need... Full story

Yahoo Finance • 4 months ago

Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end

Earnings Call Insights: Ardelyx (ARDX) Q1 2026 MANAGEMENT VIEW * “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding t... Full story

Yahoo Finance • 4 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) * Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) * Roku (ROKU [https://seekingalpha.com/symbol/ROKU]) * Twilio... Full story

Yahoo Finance • 4 months ago

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet... Full story

Yahoo Finance • 5 months ago

Ardelyx President and CEO Sells 41,000 Shares for $243,000

Michael Raab, President & CEO of Ardelyx(NASDAQ:ARDX), reported a sale of 41,666 shares of Common Stock for a transaction value of approximately $243,000 on March 16, 2026, according to a SEC Form 4 filing. Transaction summary Metric Val... Full story

Yahoo Finance • 6 months ago

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

On Feb. 24, 2026, Ardelyx(NASDAQ:ARDX) President and CEO Michael Raab reported the sale of 41,666 shares of Common Stock for approximately $261,000, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct)... Full story

Yahoo Finance • 7 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 7 months ago

Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Ardelyx, Inc. is next on our list. TheFly reported on January 29 that TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating.... Full story

Yahoo Finance • 9 months ago

BTIG Maintains a Buy on Ardelyx, Inc (ARDX)

​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earli... Full story

Yahoo Finance • 10 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 10 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH®... Full story

Yahoo Finance • 10 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studiesdemonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic hea... Full story

Yahoo Finance • 10 months ago

Ardelyx appoints Sue Hohenleitner as CFO

* Ardelyx (NASDAQ:ARDX [https://seekingalpha.com/symbol/ARDX]) announced on Monday the appointment [https://seekingalpha.com/pr/20263197-ardelyx-appoints-experienced-finance-executive-sue-hohenleitner-as-chief-financial-officer] of Sue H... Full story

Yahoo Finance • 10 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story

Yahoo Finance • 10 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet me... Full story